Back to Search Start Over

How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.

Authors :
Daldrup-Link HE
Theruvath AJ
Rashidi A
Iv M
Majzner RG
Spunt SL
Goodman S
Moseley M
Source :
Pediatric radiology [Pediatr Radiol] 2022 Feb; Vol. 52 (2), pp. 354-366. Date of Electronic Publication: 2021 May 27.
Publication Year :
2022

Abstract

Gadolinium chelates have been used as standard contrast agents for clinical MRI for several decades. However, several investigators recently reported that rare Earth metals such as gadolinium are deposited in the brain for months or years. This is particularly concerning for children, whose developing brain is more vulnerable to exogenous toxins compared to adults. Therefore, a search is under way for alternative MR imaging biomarkers. The United States Food and Drug Administration (FDA)-approved iron supplement ferumoxytol can solve this unmet clinical need: ferumoxytol consists of iron oxide nanoparticles that can be detected with MRI and provide significant T1- and T2-signal enhancement of vessels and soft tissues. Several investigators including our research group have started to use ferumoxytol off-label as a new contrast agent for MRI. This article reviews the existing literature on the biodistribution of ferumoxytol in children and compares the diagnostic accuracy of ferumoxytol- and gadolinium-chelate-enhanced MRI. Iron oxide nanoparticles represent a promising new class of contrast agents for pediatric MRI that can be metabolized and are not deposited in the brain.<br /> (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Details

Language :
English
ISSN :
1432-1998
Volume :
52
Issue :
2
Database :
MEDLINE
Journal :
Pediatric radiology
Publication Type :
Academic Journal
Accession number :
34046709
Full Text :
https://doi.org/10.1007/s00247-021-05098-5